Alien and aboriginal flora of the Amur section of the Trans-Siberian Railway and its relationships with the characteristics of natural biomes

Trans-Siberian Railway, from the settlement of Yerofey Pavlovich to Kundur-Khabarovskiy railway station, with the total length of 1043 km (11 % of the TSR)explored. The study encompassed sixteen railway stations located in two biomes, including Amur-Zeya Boreal Taiga with variants southern taiga and subtaiga, and Zeya-Bureya Nemoral Broadleaved Forests and Forest-Steppe one

Takeover as a Form of Corporate Conflict and the Process of Transfer of Stock Ownership’s Rights

The article considers the problem of corporate conflicts in the Russian practice of corporate relations in the joint-stock companies. Today, corporate relations are changing, the role of intangible resources is growing, and a 100% share in the company capital does not always guarantee control over the company. In this regard, the range of ways to acquire corporate control is expanding. The purpose of the article is to develop a classification of the methods of joint stock companies takeovers. The proposed classification differs from existing classifications by differentiating takeover methods according to the criterion “takeover tool used by the takeover initiator”. The use of this classification by companies in the development of protective mechanisms against takeovers will make it possible to choose the most appropriate and effective protective measures in a particular situation and thereby avoid some corporate conflicts

The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration

N.S. Zhayvoronok1, O.V. Kolenko1–3, L.P. Danilova1,2, E.L. Sorokin1,3 1Khabarovsk Branch of the S. Fedorov Eye Microsurgery Federal State Institution, Khabarovsk, Russian Federation 2Institute of Advanced Training of Healthcare Specialists, Khabarovsk, Russian Federation 3Far Eastern State Medical University, Khabarovsk, Russian Federation Aim: to assess the clinical efficacy of brolucizumab for choroidal neovascularization (CNV) in patients with age-related macular degeneration (AMD). Patients and Methods: clinical assessment of the efficacy of brolucizumab was performed in 25 patients (25 eyes) with neovascular AMD. The dynamic monitoring included optical coherence tomography to assess the localization and area of the neovascular complex, as well as the density and thickness of the new blood vessels (OCT-angiography). Three injections of brolucizumab (in a dose of 6 mg/0.05 mL) were performed once a month. The follow-up period was 4 months. Results: the mean age of patients was 68±5 years. After the first injection of brolucizumab, there was a statistically significant decrease in the mean values of central retinal thickness (CRT) and macular volume (MV) vs the baseline values. By month 4, a statistically significant increase in the best corrected visual acuity (BCVA) vs. that at the baseline was achieved: from 0.3 (0.2; 0.45) to 0.6 (0.4; 0.6) (p&lt;0,001). In all patients after three injections the minimal values of CRT were reported: they decreased from 298 (284; 302) to 268 (263; 270) µm. Also, MV reduced from 10.4 (9.5; 10.7) to 8.8 (8.7; 9.3) mm3 (p&lt;0,001). After one month in 22 of 25 patients and after three intravitreal injections of brolucizumab in 3 patients an adhesion of the neuro- and pigment epithelium was recorded with the complete resorption of the subretinal fluid, and the subretinal fluid was not found. Subjectively, all patients noted an improvement in the quality and contrast sensitivity of central vision after treatment. Conclusions: after each injection of brolucizumab, there was a statistically significant progressive reduction in macular parameters, CRT and MV, coupled with an increase in mean BCVA values. Keywords: vascular endothelial growth factor, anti-VEGF, brolucizumab, age-related macular degeneration, neovascular age-related macular degeneration, wet age-related macular degeneration, treatment efficacy. For citation: Zhayvoronok N.S., Kolenko O.V., Danilova L.P., Sorokin E.L. The initial results of using brolucizumab (Beovu®), an angiogenesis inhibitor, for choroidal neovascularization in patients with age-related macular degeneration. Russian Journal of Clinical Ophthalmology. 2022;22(4):228–233 (in Russ.). DOI: 10.32364/2311-7729-2022-22-4-228-233. </p

Methylomonas paludis sp. nov., the first acid-tolerant member of the genus Methylomoas, from an acidic wetland

An aerobic methanotrophic bacterium was isolated from an acidic (pH 3.9) Sphagnum peat bog in north-eastern Russia and designated strain MG30T. Cells of this strain are Gram-negative, pale-pink-pigmented, non-motile, thick rods that are covered by large polysaccharide capsules and contain an intracytoplasmic membrane system typical of type I methanotrophs. They possess a particulate methane monooxygenase enzyme (pMMO) and utilize only methane and methanol. Carbon is assimilated via the ribulose-monophosphate pathway; nitrogen is fixed via an oxygen-sensitive nitrogenase. Strain MG30T grows in a pH range of 3.8-7.3 (optimum pH 5.8-6.4) and at temperatures between 8 and 30°C (optimum 20-25°C). The major cellular fatty acids are C16:1ω5t, C16:1ω8c, C16:1ω7c, and C14:0; the DNA G+C content is 48.5 mol%. The isolate belongs to the family Methylococcaceae of the class Gammaproteobacteria and displays 94.7-96.9% 16S rRNA gene sequence similarity to members of the genus Methylomonas. However, strain MG30T differs from all taxonomically characterized members of this genus by the absence of motility, the ability to grow in acidic conditions, and low DNA G+C content. Therefore, we propose to classify this strain as a novel, acid-tolerant species of the genus Methylomonas, Methylomonas paludis sp. nov. Strain MG30T (=DSM 24973T = VKM B-2745T) is the type strain.